RSS
aflibercept
Regeneron’s supplemental biologics licence application for EYLEA gains FDA approval
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals for a supplemental biologics licence application (sBLA) for EYLEA (aflibercept) injection in patients with wet age-related macular degeneration (AMD). Read more
Mylan & Momenta Pharmaceuticals announce strategic development of biosimilar to aflibercept
A strategy for the development of a biosimilar to the vascular endothelial growth factor (VEGF) inhibitor treatment for various degenerative retinal diseases, aflibercept, has been announced by Momenta Pharmaceuticals and Mylan. Read more
